Fish oil supplementation as adjunct therapy for chronic obstructive pulmonary disease (COPD): A feasibility study

Not Applicable

• Conditions: Chronic obstructive pulmonary disease; Inflammation; Respiratory - Chronic obstructive pulmonary disease; Inflammatory and Immune System - Other inflammatory or immune system disorders; Alternative and Complementary Medicine - Other alternative and complementary medicine

• Registration Number: ACTRN12612000158864
• Lead Sponsor: Dr. Alison Hill

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Aged between 18-80 years
2. Have a clinical and spirometric diagnosis of COPD (forced expiratory volume (FEV1) <80% of predicted and best recorded ratio of FEV1 to forced vital capacity (FEV1/FVC) <0.70)
3.Stable dose of medication for 28 days prior to entering the study

Exclusion Criteria

1. Use of fish oil (>1g/day for 3 months); 2. Self-reported presence of unstable co morbidities (right heart failure, sleep disorders, metabolic pathologies); 3. Current smoker; 4. GOLD stage IV COPD (due to the high likelihood of irreversible airways remodelling); 5. a-antitrypsin deficiency; 6. Cachexia (unintentional weight loss exceeding 5% within the previous 3-12 months) or body mass index (BMI) < 18.5kg/m2; 7. Morbid obesity (BMI >40kg/m2); 8. A mini mental assessment score of <23 to ensure that participants are cognitively able to complete assessments; 9. Clinically unstable COPD; 10. Use of steroid or antibiotic medication for 28 days prior to baseline visit; 11. Patients with respiratory conditions not related to airflow limitation (e.g. primary pulmonary hypertension, post-lobectomy for lung cancer, or pulmonary fibrosis); 12. Participation in a comprehensive pulmonary rehabilitation program in the previous 2 years; 13. Intending to undertake a pulmonary rehabilitation program in the next 6 months. 14. Use of Warfarin medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incorporation of long chain omega-3 fatty acids in erythrocytes will be measured by gas chromatography following fatty acid extraction from red blood cells[Baseline (week 0) and 4 months]